OGT2115 reduced apoptosis of islet beta cells in STZ mice
Immunohistochemistry with an insulin antibody showed that STZ treatment
clearly reduced intra-islet insulin content (Fig. 4A and 4B). However,
administration of OGT2115 to STZ mice could partially improve the
intra-islet insulin level (Fig. 4A and 4B). The ratio of
insulin+/glucagon+ cells was
increased significantly in the islets of 10 mg/kg OGT2115-treated STZ
mice when compared to vehicle-treated STZ mice (Fig. 4A and 4C). TUNEL
assays showed an obvious decrease in the number of apoptotic pancreatic
beta cells in OGT2115-treated STZ mice when compared with
vehicle-treated STZ mice. Statistical analysis also confirmed the
reduced apoptotic ratio in STZ mice treated with 10 mg/kg OGT2115 (Fig.
4D).